Reprint

Cancer Biomarkers and Targets in Digestive Organs

Edited by
September 2019
146 pages
  • ISBN978-3-03921-463-1 (Paperback)
  • ISBN978-3-03921-464-8 (PDF)

This book is a reprint of the Special Issue Cancer Biomarkers and Targets in Digestive Organs that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Identification and development of cancer biomarkers and targets have greatly accelerated progress towards precision medicine in oncology. Studies of tumor biology have not only provided insights into the mechanisms underlying carcinogenesis, but also led to discovery of molecules that have been developed into cancer biomarkers and targets. Multi-platforms for molecular characterization of tumors using next-generation genomic sequencing, immunohistochemistry, in situ hybridization, and blood-based biopsies have greatly expanded the portfolio of potential biomarkers and targets. These cancer biomarkers have been developed for diagnosis, early detection, prognosis, and prediction of treatment response. The molecular targets have been exploited for anti-cancer therapy and delivery of therapeutic agents. This Special Issue of Biomedicines focuses on recent advances in the discovery, characterization, translation, and clinical application of cancer biomarkers and targets in malignant diseases of the digestive system. The goal is to stimulate basic and translational research and clinical collaboration in this exciting field with the hope of developing strategies for prevention and early detection/diagnosis of cancer in digestive organs, and improving therapeutic and psychosocial outcomes in patients with these malignant diseases.

Format
  • Paperback
License
© 2019 by the authors; CC BY-NC-ND license
Keywords
colorectal cancer; intestinal disorder; intestinal tumors; zebrafish; stereotactic body radiation therapy; immunotherapy; biomarkers; Asian Cancer Research Group (ACRG); gastric carcinoma; molecular profiling; precision therapy; pembrolizumab; predictive biomarkers; ramucirumab; The Cancer Genome Atlas (TCGA); therapeutic targets; trastuzumab; biliary tract carcinoma; chemotherapy; clinical trial; colorectal carcinoma; gastric carcinoma; gastrointestinal oncology; hepatocellular carcinoma; immunotherapy; pancreatic carcinoma; targeted therapy; Liver transplantation; liver graft injury; intragraft gene expression profiles; cell adhesion molecules; CD274; HFE; hepatocellular carcinoma; immunohistochemistry; molecular profiling; next-generation sequencing; precision medicine; predictive biomarkers; gastrointestinal oncology; pancreatic carcinoma; hepatocellular carcinoma; biliary tract carcinoma; gastric carcinoma; colorectal carcinoma; stereotactic body radiation therapy; liver transplant; targeted therapy; psychosocial support; G protein–coupled receptors; cholecystokinin; gastrin; gastrin-releasing peptide; bombesin; neurokinin; neurotensin; somatostatin; circulating tumor cells; colorectal carcinoma; CAM invasion assay; phenotypic mosaics; tumor progenitor; biomarker; gastrointestinal malignancies; immunotherapy; n/a